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Abstract
Neprilysin (NEP) is a promiscuous zinc metalloprotease with a broad substrate specificity and cleaves 
a remarkable diversity of substrates through endopeptidase action. Two of these - amyloid-β and 
natriuretic peptides - implicate the enzyme in both Alzheimer’s disease and cardiovascular disease 
respectively. Here, we report creation of a catalytically inactive NEP (E584D) to determine the first 
peptide-bound crystal structure at 2.6 Å resolution. The structure reveals key interactions involved in 
substrate binding which we have identified to be conserved in other known zinc metalloproteases. In 
addition, the structure provides evidence for a potential exosite within the central cavity that may 
play a critical role in substrate positioning. Together, these results contribute to our understanding of 
the molecular function of NEP.
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Introduction
Neprilysin (NEP, EC 3.4.24.11) is a transmembrane M13 zinc metalloprotease that exhibits 
endopeptidase activity on over 30 short peptide substrates [1,2]. Recently, NEP has received 
considerable attention for its role in amyloid-β degradation and represents a potential therapeutic 
target in Alzheimer’s disease research [3]. The enzyme is, however, better characterised for its role in 
blood pressure regulation through the degradation of several small peptide vasodilators which include 
bradykinin, substance P and natriuretic peptides [4].
The mechanism of degradation of three main classes of natriuretic peptides- atrial, B-type and C-type 
natriuretic peptides (ANP, BNP and CNP) by NEP are well documented [5]. These three classes of 
peptides have been studied for their promotion of vasodilation mediated through interaction with 
membrane guanylate cyclases and natriuretic receptors [6]. Whilst each peptide varies in length 
(between 22-32 amino acids), all share a common 17-residue central ring structure with 10 of the 17 
residues conserved [6]. Differences in amino acid sequence causes varied susceptibility to NEP 
degradation as follows - CNP>ANP>BNP [7]. Their degradation and inactivation by NEP results in 
vasoconstriction and elevated blood pressure. As such, NEP has been targeted for inhibition in order 
to elicit an antihypertensive response in patients with high blood pressure [8]. 
The molecular structure of NEP is comprised of a 27-residue intracellular domain, followed by a 23-
residue transmembrane domain and finally a 699-residue extracellular catalytic domain. To date, 
several crystal structures of the NEP extracellular domain have been reported for both substrate-free 
[9] and inhibitor-bound forms [10–15]. These structures reveal the domain is ellipsoid in shape with 
the active site contained within a large occluded cavity. The active site is based around the conserved 
metalloprotease HEXXH motif where two conserved histidine residues (His583 and His587) coordinate 
a zinc ion and the conserved glutamate (Glu584) is responsible for polarisation of a solvent molecule 
which then performs nucleophilic attack on the substrate’s scissile peptide bond [16].
It should be noted that NEP and a few other zinc metalloproteases - including endothelin-converting 
enzyme I (ECE-1) [17], insulin degrading enzyme (IDE) [18], and presequence peptidase (PreP) [19] - 
are classed as cryptidases due to the location of the active site within a large cavity [20]. Each 
cryptidase must undergo a conformational change in which the structure transitions from open, where 
substrates can access the cavity, to closed where substrates are trapped, and substrate recognition 
can occur [20]. Cryptidases range in size from 85-120kDa and can degrade a many peptide substrate 
that vary in sequence, size, shape and surface charge.  
The promiscuous nature of NEP, and other cryptidases, raises questions as to their mechanism of 
substrate specificity. NEP inhibitor-bound crystal structures have provided some insights into 
substrate specificity enabling the characterisation of S1, S1’ and S2’ [21] binding pockets at the 
catalytic site. S1’ has been reported to be the largest contributor to substrate specificity having 
preference for hydrophobic amino acids. Specificity is also achieved through the limited cavity volume 
imposing constraints on maximal substrate size. For NEP the cavity volume of approximately 5000Å3 
results in selection of peptides under 5 kDa in size [22].
Despite the number of available NEP crystal structures, a peptide-bound complex has yet to be 
reported. This can be mainly attributed to rapid cleavage of peptides by NEP, hence not ideal for X-
ray crystallography studies investigating protein-substrate binding interactions. Moreover, crystal 
growth, and subsequent data collection, of protein crystals requires lengthy periods of incubation, 
NEP would process any peptide substrate long before data collection could take place. In this study, a 
mutant NEP E584D protein was expressed and confirmed to be catalytically inactive. This protein was 
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used in the crystallographic study to prevent peptide cleavage and allow binding interactions to be 
preserved.
Here we report the structures of catalytically inactive NEP E584D in a substrate-free and peptide-
bound form. In the peptide-bound form, a C-type natriuretic peptide (CNP) is bound to the active site, 
revealing main-chain binding interactions and providing insights into the general mechanism of 
peptide interaction. These results contribute to the understanding of a key enzyme NEP that has a role 
to play in both Alzheimer’s disease and cardiovascular disease. 
Materials and Methods
All reagents used were purchased from Sigma-Aldrich or Fisher Scientific unless otherwise specified.
Plasmid construction and transfection 
cDNA encoding full length human NEP in cloning vector pMD18-T Simple was purchased from 
Sinobiology. Polymerase chain reaction (PCR) was used to, amplify the extracellular domain of NEP 
(Thr49 - Trp749), add a 5’ KpnI site and 6x histidine tag, and add a 3’ NotI site. The amplified PCR 
product and vector pPICzαA were digested with KpnI and NotI (NEB). The PCR product was then ligated 
into pPICzαA downstream of a secretion tag. This tag was transcribed with NEP for secreted protein 
expression but was cleaved after secretion.
Mutation of the NEP residue 584 from glutamate to aspartate (E584D) was conducted using PCR site-
directed mutagenesis (NEB Q5) and confirmed using DNA sequencing. The NEP pPICzαA construct was 
integrated into the genome of Pichia pastoris GS115 in accordance with the Invitrogen EasySelect 
manual (cat. no. K1740-01) and restriction enzyme SacI (NEB). A full list of primer sequences are given 
in Table 1.
Protein expression and purification
Expression of recombinant NEP and NEP E584D extracellular domains from the Pichia pastoris GS115 
was performed in accordance with the Invitrogen EasySelect manual. Briefly, a pre-induction culture 
was incubated for 24 hours in Buffered Glycerol-complex Medium (BMGY) to generate the desired cell 
density. Media was changed to Buffered Methanol-complex Medium (BMMY) for a 72-hour induction. 
100% methanol was added at 24 and 48 hours to maintain the methanol concentration.
After induction the supernatant was harvested by centrifugation at 6000 RCF for 20 min at 4°C. Trizma 
and NaCl was added to the supernatant to give final concentrations of 25 mM Trizma and 150 mM 
NaCl. The supernatant was then centrifuged at 6000 RCF for 20 min at 4°C and filtered through a 
0.22μm filter (Millipore).
Supernatant was loaded onto a 5 mL HisTrap affinity column (GE Healthcare Life Sciences) at 
5 mL min−1 pre-equilibrated with Buffer A (25 mM Trizma, 150 mM NaCl and 2 mM MgCl2 pH 7.5). 
After loading the column was washed with 2% Buffer B (25 mM Trizma, 150 mM NaCl, 2 mM MgCl2 
and 500 mM imidazole pH 7.5) until the UV trace returned to baseline. NEP was eluted using a single 
50% Buffer B wash. Protein containing fractions were pooled and concentrated into 1 mL using a 30 
kDa Millipore centrifuge filter. The concentrated NEP was loaded onto a 16/60 Superdex HiLoad 200 
column for size exclusion. Again, protein containing fractions were pooled and stored at 4 °C for short 
term storage or −20 °C for longer term storage. SDS-PAGE was used to confirm presence and purity of 
NEP after purification.
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Enzyme assay
The activity of NEP and NEP E584D were assessed by measuring cleavage of the fluorogenic peptide 
Mca-RPPGFSAFK-(Dnp) (Enzo Life Sciences) [23]. Protein was diluted to a concentration of 31.3nM in 
Buffer A. 50 µL of diluted protein was added to a black 96 well microplate (cat. no. 655076, Greiner 
Bio-One). 50 µL of 100 μM Mca-RPPGFSAFK-(Dnp), dissolved in Buffer A with 10% DMSO, was added 
to a black 96 well microplate (Greiner Bio-One) to initiate the reaction. 
Each fluorescence assay was conducted in triplicate. Fluorescence was recorded at 20 second intervals 
for a length of 35 minutes on a CLARIOstar high-performance microplate reader (BMG LABTECK). 
Excitation was achieved at 328 nm and emission was detected at 393 nm [9].
Circular dichroism 
The secondary structure composition of NEP and NEP E584D was analysed using circular dichroism. 
Protein samples of NEP and NEP E584D were diluted to 2.725 µM and 2.6 µM respectively before 
analysis.  Data were collected in triplicate using a 1 mm quartz cuvette and a Chirascan circular 
dichroism spectrometer at 20ºC. The wavelength scanning range was between 200-300 nm with a 1 
nm step size, monochromator bandwidth of 3 nm and sample time-per-point of 3 seconds. 
Crystallisation
Protein crystallisation was performed using sitting drop vapour diffusion. NEP E584D (8 mg/mL) was 
dispensed with a Phoenix crystallisation robot (Art Robbins Instruments) into an Intelli-Plate 96 (cat. 
no. 102-0001-03, Art Robbins Instruments) at a ratio of 0.2 µL: 0.2 µL protein to crystallisation buffer. 
Crystallisation buffer for the substrate-free structure was 0.16 M potassium nitrate, 0.04M sodium 
bromide, 0.02 M bis-tris propane and 20% (w/v) PEG 3350. Crystallisation plates were incubated at 
18 °C and crystals formed within two months. 
Attempts to co-crystallize NEP E584D with peptide were unsuccessful. Instead the peptide-bound 
structure was achieved through soaking. Crystals for soaking were generated using crystallisation 
buffer 0.16 M potassium nitrate, 0.04 M sodium iodide and 20% (w/v) PEG 3350. Again, crystallisation 
plates were incubated at 18 °C and crystals formed within two months. Once formed 0.2 µl of 9.1 mM 
C-type natriuretic peptide was added to the crystallisation drops and incubated for a further 14 days 
at 18 °C before data collection. The C-type natriuretic peptide used had the amino acid sequence 
‘GLSKGCFGLKLDRIGSMSGLGC’ and was sourced from GenScript (Cas. No. 127869-51-6). All crystals 
used for data collection were flash-cooled in liquid nitrogen for storage without the use of 
cryoprotectant. 
X-ray data collection and refinement
X-ray diffraction data collection for the NEP E584D substrate-free and peptide-bound structures was 
conducted on Diamond Light Source (Didcot, Oxford UK) beamlines I04 (mx17212-37) and I04 
(mx17212-46) respectively. At the time of collection both beam lines were fitted with Eiger2 X 16M 
detectors.
X-ray diffraction data were indexed and integrated using DIALS [24]. Data were scaled and merged 
using AIMLESS [25,26] where resolution cut offs were applied. The structures were solved by 
molecular replacement using Phaser [27] and substrate-free neprilysin (6GID) [9]. Programs Refmac5 
[28] and Coot [29] were used for refinement of the structures.
Validation of the structures was achieved using programs MolProbity [30] and PDB validation [31]. All 
structural images and superpositions were generated in CCP4mg [32]. Final refined structures were 
deposited in the PDB under codes 6SH1 and 6SH2.
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Results and Discussion
Catalytic inactivation of NEP
To investigate peptide binding interactions, it was necessary use catalytically inactive NEP. Inactive 
NEP could not perform peptide cleavage and hence allowed protein-peptide interactions to be 
preserved in crystallisation experiments. Similar crystallographic approaches  have successfully been 
reported in the study of protein-peptide binding interactions with other catalytically inactive zinc 
metalloproteases [18,33].
Catalytic inactivation of NEP was achieved by mutation of active site glutamate 584 to an aspartate 
(E584D). DNA sequencing, as described in materials and methods, was used to confirm the presence 
of this mutation. The extracellular domain of NEP E584D was then expressed in Pichia pastoris. In the 
following results section, the extracellular domain of NEP E584D will be referred to as just NEP E584D. 
Activity of NEP E584D was measured using a fluorescence assay (Fig. 1). Unlike wild-type NEP, NEP 
E584D showed loss of catalytic activity. While no activity for NEP E584D was observed over the 35-
minute assay there remained the possibility that low-level residual activity may still be present.
Circular dichroism (CD) was used to compare the secondary structure composition of NEP and NEP 
E584D. The high degree of similarity in CD traces confirmed that mutation E584D did not induce 
secondary structure variation (Fig. 2). As such, NEP E584D protein was considered suitable for 
crystallisation experiments.
Comparisons of NEP E584D and wild-type NEP substrate-free crystal structures
X-ray crystallography data for substrate-free NEP E584D were collected and the crystal structure 
(6SH1) was determined in the monoclinic space group P21 to a resolution of 2.1 Å. It should be noted 
that several lower resolution X-ray crystallography data sets for substrate-free NEP E584D were 
collected and solved in the more frequently observed P3221 space group. Details of data collection 
and refinement statistics are listed in Table 2. The substrate-free structure of NEP E584D was used to 
determine whether the presence of mutation E584D caused significant structural perturbation from 
wild-type NEP. 
Previously, we had reported the structure of wild-type substrate-free NEP (6GID) [9] to a resolution of 
1.9 Å. This wild-type structure adopted a closed conformation and revealed the position of active site 
residues in a substrate-free state. Wild-type substrate-free NEP (6GID) was superimposed onto 
substrate-free NEP E584D (Fig. 3a). A root-mean-square deviation (RMSD) value of 0.57 Å, calculated 
using a least squares comparison for α-carbon residues 54–749, confirmed the overall structure had 
been preserved. The high degree structural similarity also confirmed that variation in space group 
between P3221 and P21 did not cause structure changes due to crystal packing. NEP E584D remained 
in a closed conformation and contained the same four glycosylation sites. Electron density for the zinc 
ion remained clear and only minimal movement was present in residues surrounding or involved in 
zinc coordination (Fig. 3b). The only notable difference between wild-type and E584D substrate-free 
NEP structure was the molecule that provided additional coordination to the zinc ion. In wild-type 
substrate-free NEP a phosphate ion coordinates the zinc ion while in substrate-free NEP E584D a single 
water coordinates the zinc ion. The similarities between wild-type and mutant structures supported 
the view that NEP E584D was an appropriate model to study peptide binding interactions. Fourier 
electron density maps of residue 584 in NEP and NEP E584D highlight the presence of the mutation 
(Fig. 3c).  
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Peptide-bound crystal structure of NEP E584D
The peptide-bound crystal structure of NEP E584D (6SH2) was determined in the trigonal space group 
P3221 to a resolution of 2.6 Å. The active site of NEP E584D, contained within the large central cavity, 
had sufficient electron density to model a four-residue peptide product from the 22-residue long C-
type natriuretic peptide (CNP) (Fig. 4). These modelled residues occupied the S1, S1’, S2’ and S3’ 
subsites that previously characterised in inhibitor-bound structures [10–15].
Previous  high-performance liquid chromatography data for CNP has reported at least 6 cleavage sites 
are targeted by NEP [34]. The ability of NEP to cleave CNP at several distinct positions dictates that in 
a single protein crystal the residues of CNP interacting with the active site will be different in individual 
NEP molecules. Therefore, from the experimental X-ray crystallography data, whilst we were able to 
ascertain the mode of peptide binding for the α-carbon main-chain, we could not model the specific 
side-chains that occupy the S1-S3’ subsites. Perhaps with higher resolution data it may be possible to 
identify the most common residues occupying these subsites in the conditions tested.
For the best interpretation of the electron density for CNP and to provide information on the mode of 
peptide binding, a poly-alanine tetra-peptide was modelled bound in the NEP E584D active site (Fig. 
5a). A Fo-Fc Fourier difference map showed some continuation of electron density in areas of 
unmodelled side chains. Additional density was observed at the N- and C- terminus of the modelled 
peptide chain indicating the presence of additional residues that could not be resolved. The majority 
of CNP could not be modelled, suggesting much of the peptide is flexible (disordered) and does not 
exhibit tight binding interactions with the cavity lining. This also indicates that the modelled P1, P1’, 
P2’ and P3’ residues are likely to be the primary site of interaction between NEP E584D and the 
peptide. An alternative possibility is that peptide cleavage had occurred due to low level protease 
activity undetected while performing enzyme assay measurements. However, the observed electron 
density between P1 and P1’ was continuous indicating that no cleavage had occurred in the peptide 
fragment that was modelled.
Despite the inability to model the side chains of CNP, several binding interactions could be identified 
between the modelled poly-alanine main chain of CNP and NEP E584D (Fig. 5b). Based on our 
interpretation of the electron density we suggest that Asn542 and Ala543 interact with the amino 
group of P1’. Asn542 also interacts with the carboxyl group of P2’. Arg717 interacts with the carboxyl 
group of P1’ and additional interactions are provided through coordination of the zinc ion by the 
carboxyl group of the P1 residue. Interestingly, these main chain interactions induce a >90º bend in 
the CNP around the P1’ residue and their importance has been highlighted in previous inhibitor-bound 
structures. Phosphoramidon, a generic metallo-endopeptidase inhibitor, exhibits very similar binding 
interactions to the zinc ion, Asn542, Ala543 and Arg717 (Fig. 6a) [10]. This is also true of sacubitril, a 
NEP specific inhibitor, where all interactions except those from Ala543 are observed [15]. 
Further, residues Asn542, Ala543 and Arg717 are conserved in other metalloproteases including the 
previously mentioned cryptidases IDE, PreP and ECE-1. Peptide-bound structures for both IDE (2G47) 
and PreP (2FGE) reveal identical binding interactions to these conserved residues, leading to a highly 
similar peptide orientation. A superposition of peptide-bound NEP E584D and IDE structures (2G47) 
illustrates this observation (Fig. 6b). The high degree of similarity in peptide binding further validates 
our peptide-bound NEP E584D structure. In the absence of a peptide-bound structure of ECE-1, we 
predict a similar mode of peptide binding given the high structural homology to NEP. 
In addition to the main chain interactions discussed above, peptide binding will also involve side-chain 
interactions. Whilst the side chains for CNP P1-P3’ residues have not been modelled, the position of 
modelled β-carbons allows prediction of subsite residues that are important for protein-peptide 
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interactions (Figs. 5 and 7). The β-carbons for P1’ and P2’ are orientated towards NEP E584D residues 
therefore side chains are likely to have important roles in peptide binding. In contrast, P1 and P3’ side 
chains are orientated into the cavity centre and are therefore unlikely to have close interactions with 
S1 and S3’ sites. 
The S1’ and S2’ sites have been characterised in inhibitor-bound structures [10–15] and exhibit several 
binding interactions. The S1’ site is a hydrophobic pocket resulting in the reported preference of NEP 
to cleave substrates at the amino side of hydrophobic residues. S2’ has been reported to have a 
preference for hydrophobic residues and can accommodate bulky side chains due to the movement 
involving residues Arg110, Arg102 and Phe106 [35,36]. 
Putative exosite
Additional unexplained electron density was observed in a proximal site approximately 14 Å away 
from the zinc ion in the peptide-bound NEP E584D structure (Fig. 8a). This density was completely 
absent in the substrate-free NEP E584D structure. It is likely that this density corresponds to a portion 
of CNP interacting with residues of the NEP E584D cavity. These interactions may anchor the peptide 
and explain why electron density is observed in this specific area. Whilst the exact region of CNP 
cannot be identified from electron density, the shape and size of the density can be accounted for by 
an amino acid residue (Fig. 8b). The modelled residue is orientated such that the electron density 
continues beyond the carboxyl and amino groups and the β-carbon is positioned towards polar 
residues Asp208, His217 and Tyr346 possibly indicating a preference for a polar residue in that 
location.
Similar electron density feature has been observed and reported in a peptide-bound structure of 
insulin-degrading enzyme (IDE) [18]. IDE, like NEP, is a zinc metalloprotease that degrades several 
small peptide substrates and possesses a catalytic site that is located within a large central cavity. In 
the peptide-bound structure of IDE, electron density was observed for residues around the catalytic 
zinc in addition to the proximal site. This proximal or exosite in IDE has been proposed to be important 
for positioning the peptide such that the correct residues are localised to the active site.  
Whilst the peptide-bound structure reported here provides a strong indication for the presence of an 
exosite, complete certainty in the orientation of the interacting amino acid residue is lacking. 
Therefore, the peptide-bound structure has been submitted without this residue modelled. It is likely 
that higher resolution X-ray crystallography data may provide clarity to the existence of an exosite.
Conclusions
In summary, determination of a peptide-bound NEP E584D has revealed key binding interactions 
between protein and CNP. The main chain interactions observed for the P1-P3’ residues are likely to 
be shared for all other NEP substrates.
Given that NEP peptide cleavage can occur at many locations where residue identity is varied, we 
conclude that peptide binding interactions between the main chain of P1-P3’ and NEP E584D residues 
Asn542, Ala543 and Arg717 are most crucial for binding. These important interactions are conserved 
in cryptidases ECE-1, IDE and PreP. Additional interactions provided by the side chains of P1’ and P2’ 
residues will contribute to substrate selectivity but may not be as essential to binding. 
Peptide residues not localised to the active site are likely to exhibit a high degree of flexibility within 
the central cavity, explaining the inability to identify them in this crystal structure. There was however 
an area of strong electron density observed in a site proximal to the active site. Similar density in a 
crystal structure of IDE has been reported as an exosite. While not fully clear, such sites might prove 
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to be critical for peptide binding by conferring the correct positioning of residues within the active site 
for cleavage. Further higher-resolution crystal structures may allow larger portions of the peptide to 
be resolved thereby providing additional information on peptide binding.
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Figure legends 
Figure 1. Enzymatic assay confirming NEP E584D inactivation. NEP or NEP E584D was incubated with 
reporter peptide Mca-RPPGFSAFK(Dnp). Cleavage of the reporter peptide produces detectable 
fluorescence which is recorded over time. Above, assays for Mca-RPPGFSAFK(Dnp) cleavage by NEP 
or NEP E584D are shown. The average of three assays has been plotted at each data point with 
standard error bars. 
Figure 2. Circular dichroism comparison between wild-type NEP and NEP E584D. The overlapping 
traces confirm NEP E584D has the same secondary structure composition as wild-type NEP and are 
indicative of a largely α-helical protein. 
Figure 3. Comparison of NEP and NEP E584D crystal structures. (a) a superposition of the substrate-
free NEP (6GID) (pink) and NEP E584D (6SH1) (turquoise) crystal structures. (b) a stereo view of the 
superimposed active site residues. Electron density for residues E584 (6GID) and D584 (6SH1) (c). 2Fo-
Fc maps are set to a contour level of 1σ. 
Figure 4. Electrostatic surface representation of NEP E584D (6SH2) with bound CNP. The location of 
bound peptide (yellow) is shown with the catalytic zinc ion (orange).  
Figure 5. CNP electron density and binding interactions. (a) the modelled peptide fragment is shown 
with localised 2Fo-Fc and Fo-Fc omit electron density maps (6SH2). 2Fo-Fc and Fo-Fc maps are set to 
contour levels of 1σ and 3σ respectively. (b) a stereo view of the modelled peptide fragment with 
surrounding active site residues. Close range interactions are marked with dashed lines. 
Figure 6. Comparison of conserved active site residues and their role in substrate/inhibitor binding. 
Stereo views of peptide-bound NEP E584D (6SH2) (blue) superimposed onto (a) the Phosphoramidon-
bound NEP structure (1DMT) (green) and (b) peptide-bound IDE structure (2G47) (green).  The P1-P3’ 
residues of the bound peptide in NEP E584D are shown in yellow. Phosphoramidon and IDE bound 
peptide are shown in magenta. Close range interactions between peptide and protein are marked with 
dashed lines.
Figure 7. Schematic of binding interactions between NEP E584D and P1, P1’ and P2’ residues of CNP. 
Figure 8. Putative exosite electron density and nearby residues. (a) 2Fo-Fc and Fo-Fc omit electron 
density maps for the putative exosite with close NEP E584D amino acids (6SH2). 2Fo-Fc and Fo-Fc 
maps are set to contour levels of 1σ and 3σ respectively. (b) an alternative orientation of the exosite 
density with modelled alanine presented as a stereo view.
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Table 1. Primer sequences used for NEP E584D clone creation.
Cloning in pPICzαA Primer sequence
Forward CGCTGGTACCCATCACCACCACCATCACGAATTCCGGACCTACGATGATGGTATTTGC
AAG
Reverse GCTTGCGGCCGCTCACCAAACCCGGCACTTC
Mutagenesis
Forward CATAGGACACCAAATCACCCATGGCTTCG
Reverse ACCATGCCGATGCCCCCA
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Table 2. NEP E584D X-ray crystallography and refinement statistics.
Substrate-free Peptide-bound
Beamline I04, DLS I03, DLS
Wavelength (Å) 0.9795 0.9762
Crystallographic statistics
Space group P21 P3221
Unit cell dimensions
a,b,c (Å) 76.14, 99.75, 100.12 109.27, 109.27, 112.58
α, β, γ (º) 90.00, 106.23, 90.00 90.00, 90.00, 120.00
Resolution range (Å) 69.22-2.10 (2.14-2.10) 72.44-2.60 (2.72-2.60)
R merge 0.178 (3.676) 0.144 (6.977)
CC1/2 0.992 (0.464) 1.000 (0.604)
⟨I/σ (I)⟩ 6.6 (1.0) 17.3 (1.0)
Completeness (%) 99.9 (99.8) 100 (100)
No. observed reflections 576297 (32234) 973293 (107982)
No. unique reflections 83834 (4581) 24386 (2945)
Multiplicity 6.9 (7.0) 39.9 (36.7)
Refinement statistics
Rwork /Rfree (%) 21.94/26.35 24.43/28.82
R.m.s deviations
Bond lengths (Å) 0.003 0.002
Bond angles (º) 1.212 1.148
Ramachandran statistics
Favoured (%) 97 96
Allowed (%) 3 4
Outliers (%) 0 0
Wilson B-factor (Å2) 39.9 84.3
Average B-factors (Å2)
Protein atoms 44.54 102.18
Ligand atoms - 104.16
Water molecules 42.67 62.68
Zinc ion 34.10 81.62
No. of atoms
Protein 11226 5512
Ligand - 19
Water 495 1
Zinc ion 2 1
PDB code 6SH1 6SH2
Values in parentheses are for highest-resolution shell.
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